# A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL

> **NCT07522801** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Philippe ROUSSELOT** · enrollment: 93 (estimated)

## Conditions studied

- LAL

## Interventions

- **DRUG:** Venetoclax + Tofacitinib
- **DRUG:** Venetoclax+ Everoliumus +Enrylaze
- **DRUG:** Venetoclax + 5 Azacitidine

## Key facts

- **NCT ID:** NCT07522801
- **Lead sponsor:** Philippe ROUSSELOT
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-12-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07522801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07522801, "A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07522801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*